Fixed-dose combinations in pharmacotherapy of chronic venous diseases
Open Access
- 17 November 2024
- journal article
- Published by Remedium, Ltd. in Ambulatornaya khirurgiya = Ambulatory Surgery (Russia)
- Vol. 21 (2) , 44-51
Abstract
Chronic venous diseases are the most common vascular diseases of the lower extremities, negatively affecting all components of the quality of life in the modern society. Due to their high prevalence, the prevention and treatment of chronic venous diseases are one of the priorities of national healthcare systems in industrially developed countries. In recent years, numerous experimental and clinical studies have uncovered an important role of vascular inflammation and endothelial dysfunction in the pathogenesis of chronic venous diseases, which determine not only a wide range of vein-specific symptoms, but are also the main drivers of pathological remodelling of the vein wall and its valve apparatus, followed by the development of varicose syndrome and more severe chronic venous insufficiency. Modern knowledge of the pathogenesis of chronic venous diseases enables us to identify several priority strategies aimed at managing the basic pathophysiological mechanisms of the development and progression of the disease. Pharmacotherapy with phlebotropic drugs is one of them. Some of these drugs are able to inhibit the vein-specific inflammation, improve the microcirculatory bed regulation, increase the vein tone and contractility and, as a result, have a positive effect on the clinical signs of chronic venous disease. This review presents the mechanism of action of a phlebotropic drug that is new to the Russian Federation. It is a combination of Ruscus aculeatus extract (Ruscus extract) with hesperidin methyl chalcone (HMC) and ascorbic acid. Studies showed a high level of evidence of clinical efficacy and safety of this drug for the treatment of patients with various forms of chronic venous diseases. Due to the unique features of its mechanisms of action, the optimal focus groups for its use may include patients of different age groups with early-stage disease, in which vein-specific symptoms predominate, and patients with chronic venous oedema.Keywords
This publication has 55 references indexed in Scilit:
- Oil/water interface behavior of hesperidin methylchalcone and its application in nano-emulsionsFood Chemistry, 2024
- Hesperidin Methyl Chalcone reduces extracellular Aβ(25-35) peptide aggregation and fibrillation and also protects Neuro 2a cells from Aβ(25-35) induced neuronal dysfunctionBioorganic & Medicinal Chemistry, 2023
- A narrative review on the role of hesperidin on metabolic parameters, liver enzymes, and inflammatory markers in nonalcoholic fatty liver diseaseFood Science & Nutrition, 2023
- Response to “Re: European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. MG. De Maeseneer et al. Eur J Vasc Endovasc Surg 2022;63:184–267”European Journal of Vascular and Endovascular Surgery, 2022
- Platycodin D Inhibits β-Amyloid-Induced Inflammation and Oxidative Stress in BV-2 Cells Via Suppressing TLR4/NF-κB Signaling Pathway and Activating Nrf2/HO-1 Signaling PathwayNeurochemical Research, 2021
- Phlebotonics for venous insufficiencyCochrane Database of Systematic Reviews, 2016
- Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1European Journal of Vascular and Endovascular Surgery, 2015
- Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: Role of TRPV1, oxidative stress, cytokines and NF-κBChemico-Biological Interactions, 2015
- The Epidemiology of Chronic Venous Insufficiency and Varicose VeinsAnnals of Epidemiology, 2005
- Criteria and Recommendations for Vitamin C IntakeJAMA, 1999